Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 25 September 2017
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
  
 
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Ms E Walmsley
 
b)
 
Position/status
 
Chief Executive Officer
 
c)
 
Initial notification / amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Following the vesting on 23 September 2017 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Walmsley will receive a cash payment of £279,198.61 less applicable tax withholding in respect of 18,970.518 notional Ordinary Shares.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
£14.7175
 
18,970.518 notional Ordinary Shares
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-09-23
 
f)
 
Place of the transaction
 
n/a
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Mr R G Connor
 
b)
 
Position/status
 
President, Global Manufacturing & Supply
 
c)
 
Initial notification / amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Following the vesting on 23 September 2017 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £111,679.44 less applicable tax withholding in respect of 7,588.207 notional Ordinary Shares.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
£14.7175
 
7,588.207 notional Ordinary Shares.
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-09-23
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Mr D S Redfern
 
b)
 
Position/status
 
Chief Strategy Officer
 
c)
 
Initial notification / amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Following the vesting on 23 September 2017 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £111,679.44 less applicable tax withholding in respect of 7,588.207 notional Ordinary Shares.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
£14.7175
 
7,588.207 notional Ordinary Shares
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-09-23
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Ms C Thomas
 
b)
 
Position/status
 
SVP, Human Resources
 
c)
 
Initial notification / amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Following the vesting on 23 September 2017 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £111,679.44 less applicable tax withholding in respect of 7,588.207 notional Ordinary Shares.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
£14.7175
 
7,588.207 notional Ordinary Shares
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-09-23
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
1.
 
Details of PDMR/person closely associated with them ('PCA')
 
a)
 
Name
 
Dr P J T Vallance
 
b)
 
Position/status
 
President, Pharmaceuticals
 
c)
 
Initial notification / amendment
 
Initial notification
 
2.
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
 
Name
 
GlaxoSmithKline plc
 
b)
 
LEI
 
5493000HZTVUYLO1D793
 
3.
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
 
Description of the financial instrument
 
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)
 
Nature of the transaction
 
Following the vesting on 23 September 2017 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £139,599.30 less applicable tax withholding in respect of 9,485.259 notional Ordinary Shares.
 
c)
 
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
£14.7175
 
9,485.259 notional Ordinary Shares
 
d)
 
Aggregated information
 
Aggregated volume Price
 
n/a (single transaction)
 
e)
 
Date of the transaction
 
2017-09-23
 
f)
 
Place of the transaction
 
n/a
 
 
 
 
  
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: September 25, 2017 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc